Moderna, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stéphane Bancel
- Full Time Employees
- 4,700
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Company News
Moderna Earnings Preview: The Melanoma Breakthrough Is Real, But $221 Is Way Too Much
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial
Could Investing in Moderna's Stock Double Your Money?
Moderna, Inc. $MRNA Stock Sold by Bank Julius Baer & Co. Ltd Zurich
Buy Moderna Stock Before Q3 Earnings? Here's What to Know
If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started
Stock Split Watch: Is Moderna Next?
Moderna, Merck eye FDA approval for promising cancer vaccine
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
Will Moderna Soar on Nov. 6?
Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's work
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Run